Plain-language, PubMed-cited guides on what peptides actually do, how they're studied, and what the evidence really supports — written for people who want facts, not a pitch.
Compounds
Deep-dive guides on individual peptides, organized by what researchers actually study them for.
Essentials
New to this? These five guides cover the ground rules before you go compound-by-compound.
New to this topic? Start here — explained in plain language, no prior science background needed.
What's regulated, what's changing, and how to read FDA compounding updates correctly.
Common reported side effects, red flags worth taking seriously, and how research handles risk.
Short video breakdowns and walkthroughs — the same research, explained on camera.
In-depth articles on peptide research, individual response, clinical data, and what the science actually says.
News
Short, sourced reads on what's changing in peptide research, compounding, and regulation.
What the FDA's latest move could mean for the future of peptide medicines.
What the latest Phase 3 trial data on retatrutide actually shows — and why “Phase 3” doesn't mean approved.
Samsung Biologics' tender offer for PolyPeptide Group signals major-manufacturer confidence in peptide medicine's future.